Director Timothy Wright receives 105K AGEN (NASDAQ: AGEN) stock options grant

Rhea-AI Filing Summary

AGENUS INC director Timothy Wright received a stock option grant as equity compensation. The award covers 105,000 shares of common stock at an exercise price of $3.90 per share, expiring on April 24, 2036. The option was granted under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan and vests on the one-year anniversary of the grant date. Following this grant, Wright holds stock options for 105,000 underlying shares directly.

Insights

Equity compensation analyst

Routine director stock option grant; compensation-related, not a market trade.

Timothy Wright, a director of AGENUS INC, received a grant of stock options covering 105,000 shares of common stock at an exercise price of $3.90 per share. The options expire on April 24, 2036, indicating a long-term incentive structure.

The filing classifies this as an acquisition via grant or award, not an open-market purchase or sale. The option vests on the one-year anniversary of the grant date under the company’s 2019 Amended and Restated Equity Incentive Plan, aligning director compensation with shareholder outcomes over time.

After this grant, Wright’s reported holdings in this option series total 105,000 underlying shares with direct ownership. There are no remaining derivative positions listed beyond this grant, and no references to Rule 10b5-1 trading plans or same-day sales in the provided data.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Wright Timothy

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	105,000	$0.00	--

Holdings After Transaction: Stock Option — 105,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option shares granted: 105,000 shares Exercise price: $3.90 per share Total option shares after grant: 105,000 shares +2 more

5 metrics

Option shares granted 105,000 shares Stock option award underlying common stock

Exercise price $3.90 per share Stock option strike price

Total option shares after grant 105,000 shares Total options following transaction

Expiration date April 24, 2036 Option expiration

Transaction code A (Grant, award, or other acquisition) Form 4 transaction classification

Key Terms

Stock Option, Equity Incentive Plan, exercise price, vests, +1 more

5 terms

Stock Option financial

"security_title: "Stock Option""

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Equity Incentive Plan financial

"awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan"

An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

exercise price financial

"conversion_or_exercise_price: "3.9000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests financial

"and vests on the one-year anniversary of the grant date"

expiration date financial

"expiration_date: "2036-04-24T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wright Timothy

(Last) (First) (Middle)

C/O AGENUS INC.

3 FORBES ROAD

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AGENUS INC [ AGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$3.9	04/24/2026		A		105,000		(1)	04/24/2036	Common Stock	105,000	$0.00	105,000	D

Explanation of Responses:

1. Option awarded in accordance with the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan, and vests on the one-year anniversary of the grant date.

	/s/Austin Charette, as Attorney-in-Fact for Timothy Wright	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did AGEN (AGENUS INC) director Timothy Wright report in this Form 4?

Timothy Wright reported receiving a stock option grant for 105,000 shares of AGENUS INC common stock. The options were awarded as compensation, not bought on the open market, and give him the right to purchase shares at a fixed exercise price of $3.90 per share.

Is Timothy Wright’s Form 4 transaction in AGEN stock a buy or a grant?

The Form 4 shows a grant, not an open-market buy, coded as an acquisition by award. Wright received stock options with a $3.90 exercise price as part of equity compensation, rather than paying cash in the market to purchase AGENUS INC common shares directly.

How many AGENUS INC shares are covered by Timothy Wright’s new stock options?

The new stock option grant covers 105,000 underlying shares of AGENUS INC common stock. This entire amount is reflected as his total options following the transaction, indicating the award itself established his reported position in this particular option grant series.

When do Timothy Wright’s AGEN stock options vest and expire?

The options vest on the one-year anniversary of the grant date, according to the footnote. They carry an expiration date of April 24, 2036, giving Wright a long window after vesting to decide whether and when to exercise his right to buy the shares.

What is the exercise price of Timothy Wright’s AGENUS INC stock options?

The stock options have an exercise price of $3.90 per share for AGENUS INC common stock. This means Wright can choose to buy shares at $3.90 once vested, regardless of the market price at that time, until the options expire in April 2036.

Are Timothy Wright’s AGEN stock options part of a company equity plan?

Yes. The footnote states the option was awarded under the Agenus Inc. 2019 Amended and Restated Equity Incentive Plan. This indicates the grant is standard, plan-based director compensation designed to align his interests with long-term shareholder value in AGENUS INC.